In summary, we constructed a CRGs prognostic model based on CAFs in patients with BLCA and identified five key prognostic genes like POF1B, ARMCX1, ALDOC, C19orf33, and KRT13. Our model could predict drug sensitivity and determine the immune status of patients with BLCA. Here, C19orf33 is linked to bladder transitional cell carcinoma.